Data presented at ECTRIMS highlights long-term efficacy of Enspryng in neuromyelitis optica spectrum disorder.

These data include abstracts highlighting new longer-term efficacy and safety for Enspryng, as well as ongoing efforts to evaluate the impact of the COVID-19 pandemic for people living with MS. Additional data will show how a deeper scientific understanding of NMOSD in diverse patient populations could help ensure access to treatment.

New longer-term results from the SAkuraStar and SAkuraSky OLE studies for Enspryng will show efficacy observed in the pivotal trials is sustained with high proportions of patients remaining free from relapse over four years of treatment. Similarly, safety data from the SAkuraStar and SAkuraSky OLE studies will show the favorable safety profile of Enspryng is sustained with longer-term treatment. Enspryng has been approved in 58 countries globally, including in the U.S. as the first and only subcutaneous treatment for adults with anti-aquaporin-4 antibody (AQP4-IgG) seropositive NMOSD. Enspryng has also been approved for both adults and adolescents in the European Union, Japan, Canada and Switzerland.

The study design will be presented for SAkuraBONSAI, a prospective, open-label study of Enspryng to generate data to further the understanding of the disease activity and mechanism of action of Enspryng in patients living with AQP4-IgG seropositive NMOSD who are treatment naïve or where prior rituximab (or biosimilar) treatment has failed. Other presentations will examine the development of new tools and techniques to identify patients with NMOSD and assess disability better.

Studies presented at ECTRIMS include: "Novel Disability Assessment of NMOSD Derived from the CIRCLES Experience", "Exploring Steroid Tapering in NMOSD Patients Treated with Satralizumab in the Open-label Extension Period of SAkuraSky: A Case Series" and "Novel Assessment of Disability vs Cognition and Pain in NMOSD: A CIRCLES Cohort Study".